WESTMINSTER, Colo., Feb. 24, 2016 (GLOBE NEWSWIRE) -- GeneThera Inc. (OTC: GTHR). announced today that it has appointed Professor Karel Hruska as its Scientific Advisor. Professor Hruska was the Director of Veterinary Research Institute in Brno, Czech Republic (1990 to 2001) and he deals with an impact of mycobacteria on animal's and human's health. Prof. Hruska is the founder of the Biomedical Technology, Epidemiology and Food Safety Global Network and administrator of the databases of publications on paratuberculosis and Crohn's disease. He has published extensively about the role played by Mycobacterium Avium Paratuberculosis (MAP) in Crohn's disease. He has also published articles demonstrating MAP contamination in baby formula and papers about public health threat posed by mycobacteria in water, soil, plants and air. Dr. Tony Milici, CEO of GeneThera, stated "We are very excited to have Prof. Hruska as a part of our scientific team. His extensive experience and knowledge of the MAP and Crohn's research will help GeneThera achieve its scientific goals, as well to increase the level of awareness of the role MAP infection plays in the dairy industry and the development of Crohn's Disease". Professor Hruska also commented; "It is with great enthusiasm that I have accepted to serve as GeneThera's Scientific Advisor. I am very intrigued by GeneThera's technology and business strategy. I do believe it is very important to make the public aware of the potential risk mycobacteria pose to people's health, particularly children, and for the medical establishment and dairy industry to finally come to terms with this problem."

Mycobacterium Avium Paratuberculosis (MAP) is the causative agent of Johne's disease also known as Paratuberculosis. Johne's disease (JD) is a globally devastating incurable chronic inflammatory intestinal disease of dairy cow, sheep and goats. It has been estimated that over 70% of the dairy cowherd in the US alone are infected with MAP. A large number of studies have shown a relation between JD and Crohn's disease, a severe chronic inflammatory disease of the human intestine. MAP is resistant to standard pasteurization procedures. Studies published, among others, by Hruska and his collaborators have also shown baby formula samples were positive for MAP contamination.

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES and Johne's disease management system, HERDCHECK, designed to function on a highly automated molecular robotics platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES and HERDCHECK systems are designed for a host of individual diseases, the current priority being Johne's and Crohn's diseases.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT: Tony Milici MD, Ph.D. GeneThera, Inc. 303 439-2085Source:GeneThera